Full prescription coverage , reduced copayments , FDC and counselling were facilitators associated with higher adherence .
BACKGROUND Secondary prevention is cost-effective for cardiovascular disease ( CVD ) , but uptake is suboptimal .
Underst and ing barriers and facilitators to adherence to secondary prevention for CVD at multiple health system levels may inform policy .
OBJECTIVES To conduct a systematic review of barriers and facilitators to adherence/persistence to secondary CVD prevention medications at health system level .
Being Well-Informed About Statin is Associated with Continuous Adherence and Reaching Targets
Summary Background : Statins are life saving drugs in cardiovascular practice . However , they still are underprescribed in many situations despite their well-established benefits . Adherence may be improved by increased comprehension of the patients . Methods : Patients enrolled into a previous survey were r and omized into two groups as those , who were informed comprehensively ( Group 1 ) and those not ( Group 2 ) . 202 patients , all of whom were on secondary prevention , were contacted after median 15 months of follow up and evaluated whether they continued the statins , and reached targets . Results : 102 out of 202 patients were those enrolled into Group 1 , and 100 of them were those enrolled into Group 2 . In Group 1 , 62.7 % of patients were on continuous statin therapy during period betweeen initial and secondary contact , whereas , only 46 % of patients in Group 2 were on continuous statin therapy ( p = 0.017 ) . Being well-informed about  statin  increased the likelihood of being on continuous statin therapy after median of 15 months by 1.977 folds . Concerning targets , 64.7 % of those in Group 1 reached the targets , whereas , 43 % of those in Group 2 reached the targets ( p = 0.002 ) . Being well-informed about statin  increased the likelihood of having suggested targets by ATP III after median of 15 months by 2.430 folds . Conclusion : Providing patients with comprehensive knowledge about statins , even in patients , who were already on statin therapy , seems not only to improve adherence but also increase the percentage of those reaching targets
Full prescription coverage , reduced copayments , FDC and counselling were facilitators associated with higher adherence .
BACKGROUND Secondary prevention is cost-effective for cardiovascular disease ( CVD ) , but uptake is suboptimal .
Underst and ing barriers and facilitators to adherence to secondary prevention for CVD at multiple health system levels may inform policy .
OBJECTIVES To conduct a systematic review of barriers and facilitators to adherence/persistence to secondary CVD prevention medications at health system level .